

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Renji Medical Group Ltd

中國仁濟醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

**APPOINTMENT OF DIRECTOR
AND
CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board is pleased to announce that Mr. Chan has been appointed as an executive director of the Company and a member of the remuneration committee, the nomination committee and the corporate governance committee of the Company with effect from 9 September 2013.

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “Board”) of directors of China Renji Medical Group Limited (the “Company”) is pleased to announce that Mr. Chan Ka Chung (“Mr. Chan”) has been appointed as an executive director of the Company with effect from 9 September 2013.

Mr. Chan, aged 42, holds a bachelor’s degree in commerce from the University of British Columbia in Canada and a master’s degree in business administration and a post-graduate diploma in marketing from Edinburgh Business School in the United Kingdom. Mr. Chan, an investor and an entrepreneur, has been awarded the “Outstanding Entrepreneur of Guangdong” by the Guangdong Provincial Executive Association of Entrepreneurs. In addition, Mr. Chan is an inventor of certain invention patents relating to green environment technology and products. Mr. Chan also has extensive international network and in-depth professional knowledge and experience in finance.

Save for Mr. Chan being a beneficial owner of the subscriber of the unlisted warrants of the Company pursuant to a warrant subscription agreement (the “Warrant Subscription Agreement”) dated 5 July 2013, as far as the Board is aware, as at the date of this announcement, Mr. Chan does not hold any other position in the Company or any of its subsidiaries; nor did Mr. Chan hold any directorship in any other listed public company in the last three years; nor has any relationship with any other directors, senior management, or substantial or controlling shareholders of the Company. Save as disclosed from as above, Mr.

Chan does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (as defined under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company.

There is currently no service contract entered into between the Company and Mr. Chan and he will hold office until the next annual general meeting of the Company thereafter and shall be subject to retirement by rotation and re-election once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. The remuneration of Mr. Chan will be determined with reference to his duties and responsibilities to be decided at a later date by the Board.

Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of The Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong (the "Listing Rules") nor are there any other matters relating to the appointment of Mr. Chan that need to be brought to the attention of the shareholders of the Company.

The Board would like to extend its welcome to Mr. Chan on his appointment.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board is also pleased to announce that Mr. Chan has been appointed as a member of the remuneration committee, the nomination committee and the corporate governance committee of the Company with effect from 9 September 2013.

After the aforesaid appointment, the compositions of the remuneration committee, the nomination committee and the corporate governance committee of the Company are as follows:

Remuneration Committee Members: Mr. Wu Chi Keung (*Chairman*)
Mr. Chan
Mr. Kwok Chung On

Nomination Committee Members: Mr. Wu Chi Keung (*Chairman*)
Mr. Chan
Mr. Kwok Chung On

Corporate Governance Committee Members: Mr. Wu Chi Keung (*Chairman*)
Mr. Chan
Mr. Kwok Chung On
Mr. Tang Chi Chiu
Mr. Wang Jianguo
Ms. Wu Yan

GENERAL

Since the Warrant Subscription Agreement is not completed as at the date of this announcement, following Mr. Chan's appointment as an executive director of the Company, the subscription of the unlisted warrants will constitute a connected transaction of the Company under Chapter 14A of the Listing Rules and be subject to independent shareholders' approval. The Company is in the course of arm's length negotiations with Mr. Chan in relation to the entering into of a supplemental agreement to the Warrant Subscription Agreement in this regard. Further announcement(s) will be made by the Company as and when appropriate. Accordingly, a circular containing details of the said subscription of unlisted warrants and the notice of an extraordinary general meeting of the Company will also be despatched to the shareholders of the Company as soon as practicable.

By Order of the Board of
China Renji Medical Group Limited
Tang Chi Chiu
Chairman

Hong Kong, 9 September 2013

As at the date of this announcement, the board of the Company comprises three executive directors, namely Mr. Tang Chi Chiu, Mr. Chan Ka Chung and Mr. Wang Jianguo, and three independent non-executive directors, namely Mr. Kwok Chung On, Mr. Wu Chi Keung and Ms. Wu Yan.